

Ben Tran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1975943/publications.pdf>

Version: 2024-02-01

84
papers

4,768
citations

331670

21
h-index

102487

66
g-index

84
all docs

84
docs citations

84
times ranked

9298
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. <i>Internal Medicine Journal</i> , 2022, 52, 1339-1346.	0.8	9
2	Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. <i>European Urology</i> , 2022, 81, 253-262.	1.9	34
3	Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	1.1	0
4	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. <i>European Urology</i> , 2022, 81, 364-372.	1.9	70
5	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 825-832.	0.8	2
6	A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. <i>European Urology Focus</i> , 2021, 7, 1130-1136.	3.1	13
7	Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. <i>European Urology Focus</i> , 2021, 7, 752-763.	3.1	9
8	Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e204-e216.	2.9	27
9	Improving outcomes in germ cell cancers using miRNA. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110278.	3.2	9
10	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 613-620.	2.3	0
11	Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells. <i>Cancer Discovery</i> , 2021, 11, 1100-1117.	9.4	85
12	Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting. <i>International Journal of Cancer</i> , 2021, 149, 409-419.	5.1	6
13	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	1.6	83
14	A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. <i>World Journal of Urology</i> , 2021, , 1.	2.2	15
15	A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. <i>Oncology Research and Treatment</i> , 2021, 44, 547-556.	1.2	11
16	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. <i>EBioMedicine</i> , 2021, 72, 103625.	6.1	23
17	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷ Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 857-865.	5.0	191
18	Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2020, 77, 365-372.	1.9	116

#	ARTICLE	IF	CITATIONS
19	Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). <i>Cancer Medicine</i> , 2020, 9, 116-124.	2.8	17
20	Precision oncology in urothelial cancer. <i>ESMO Open</i> , 2020, 5, e000616.	4.5	3
21	Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). <i>European Journal of Cancer</i> , 2020, 132, 127-135.	2.8	8
22	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 2140-2150.	1.6	68
23	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844.	1.9	47
24	A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS603-TPS603.	1.6	10
25	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	2.9	4
26	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	11
27	Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, e97-e102.	1.1	5
28	Impact of access to novel therapies on the initial management of castrate-resistant prostate cancer: an Australian multicentre study. <i>Internal Medicine Journal</i> , 2019, 49, 1378-1385.	0.8	4
29	The value of networks in driving phase I trials: the Peter MacCallum Cancer Centre experience. <i>Chinese Clinical Oncology</i> , 2019, 8, 23-23.	1.2	0
30	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. <i>Internal Medicine Journal</i> , 2018, 48, 786-794.	0.8	6
31	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. <i>Seminars in Cancer Biology</i> , 2018, 52, 241-252.	9.6	12
32	Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e193-e199.	1.9	13
33	Precision oncology using a clinician-directed, tailored approach to molecular profiling. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 84-90.	1.1	2
34	Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. , 2018, 6, 93.		59
35	A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. <i>Investigational New Drugs</i> , 2018, 36, 886-894.	2.6	18
36	Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, e569-e577.	2.3	23

#	ARTICLE	IF	CITATIONS
37	Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).. Journal of Clinical Oncology, 2018, 36, 4505-4505.	1.6	6
38	Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.. Journal of Clinical Oncology, 2018, 36, 5040-5040.	1.6	1
39	Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 2521-2521.	1.6	9
40	Onset of neutropenia as an indicator of treatment response in the phase 3 RECURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 775-775.	1.6	9
41	Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2017, 35, 728-728.	1.6	0
42	Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 738-738.	1.6	0
43	Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 785-785.	1.6	67
44	Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer. Clinical Cancer Research, 2016, 22, 3488-3498.	7.0	26
45	The rapidly escalating cost of treating colorectal cancer in <sc>A</sc>ustralia. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 33-40.	1.1	24
46	Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. Journal of Clinical Oncology, 2016, 34, 714-720.	1.6	31
47	The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews, 2016, 42, 56-72.	7.7	432
48	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, e9-e15.	2.3	45
49	Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2500-2500.	1.6	14
50	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 3066-3066.	1.6	3
51	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. Journal of Clinical Oncology, 2016, 34, 3511-3511.	1.6	5
52	Efficacy and safety results in patients with impaired renal and hepatic function in the RECURSE trial.. Journal of Clinical Oncology, 2016, 34, 3547-3547.	1.6	3
53	Onset of neutropenia as an indicator of treatment response in the phase III RECURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 3556-3556.	1.6	5
54	First-in-man trial of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) as a continuous intravenous infusion (CIVI), in patients (pt) with advanced solid tumours.. Journal of Clinical Oncology, 2016, 34, e14025-e14025.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Supportive treatment for hematologic toxicities in the phase 3 RECURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, e15021-e15021.	1.6	5
56	Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM).. Journal of Clinical Oncology, 2016, 34, e15131-e15131.	1.6	12
57	TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECURSE trial.. Journal of Clinical Oncology, 2016, 34, 634-634.	1.6	9
58	TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.. Journal of Clinical Oncology, 2016, 34, 638-638.	1.6	3
59	Phase III RECURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.. Journal of Clinical Oncology, 2016, 34, 646-646.	1.6	7
60	Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A Global Germ Cell Cancer Group (G3) Study.. Journal of Clinical Oncology, 2016, 34, e16058-e16058.	1.6	0
61	Immune profile and survival outcomes in stage 2 colon cancer.. Journal of Clinical Oncology, 2016, 34, 3576-3576.	1.6	1
62	Prostate cancer multidisciplinary care: improving patient outcomes. Trends in Urology & Men's Health, 2015, 6, 18-20.	0.4	1
63	Patterns of care for metastatic renal cell carcinoma in Australia. BJU International, 2015, 116, 36-41.	2.5	12
64	Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. Clinical Colorectal Cancer, 2015, 14, 185-191.	2.3	42
65	Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy. Journal of Clinical Oncology, 2015, 33, 582-587.	1.6	50
66	Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool.. Journal of Clinical Oncology, 2015, 33, 518-518.	1.6	6
67	Effect of DNA-PK dependent phosphorylation of topo-I-S10 on its rate of proteasomal degradation and CPT response.. Journal of Clinical Oncology, 2015, 33, 606-606.	1.6	0
68	Can neutrophil-to-lymphocyte ratio be used to identify patients with metastatic renal cell carcinoma who may gain greater benefit from cytoreductive nephrectomy?. Journal of Clinical Oncology, 2015, 33, 490-490.	1.6	0
69	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2014, 106, dju124.	6.3	2,202
70	Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, e14558-e14558.	1.6	1
71	Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer (mCRC) patients with peritoneal disease in the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) database.. Journal of Clinical Oncology, 2014, 32, 569-569.	1.6	1
72	Tumor burden (TB) as a prognostic indicator in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 572-572.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Are the survival benefits associated with primary resection in de novo metastatic colorectal cancer (mCRC) mediated by reversal of systemic inflammation?. Journal of Clinical Oncology, 2014, 32, 464-464.	1.6	0
74	Resection of colorectal cancer (CRC) metastases in routine practice.. Journal of Clinical Oncology, 2014, 32, 599-599.	1.6	0
75	Delivery and effectiveness of adjuvant therapy for stage III colon cancer in routine clinical practice.. Journal of Clinical Oncology, 2014, 32, e14540-e14540.	1.6	1
76	Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care.. Journal of Clinical Oncology, 2014, 32, e17637-e17637.	1.6	0
77	Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer.. Journal of Clinical Oncology, 2014, 32, e14518-e14518.	1.6	0
78	Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. International Journal of Cancer, 2013, 132, 1547-1555.	5.1	76
79	Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)?. Journal of Clinical Oncology, 2013, 31, 410-410.	1.6	1
80	Metastatic colorectal cancer (mCRC) with primary in situ: An Australian registry.. Journal of Clinical Oncology, 2013, 31, 498-498.	1.6	1
81	Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, 3598-3598.	1.6	0
82	Platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: A translational case series.. Journal of Clinical Oncology, 2012, 30, 217-217.	1.6	9
83	Impact of renal impairment and granulocyte colony stimulating factor (GCSF) on bleomycin-induced pneumonitis (bleo lung), febrile neutropenia (FN), and survival in patients (pts) with germ cell tumor (GCT) treated with chemotherapy (chemo).. Journal of Clinical Oncology, 2012, 30, 328-328.	1.6	0
84	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer, 2011, 117, 4623-4632.	4.1	624